Study of rhASB in Patients With Mucopolysaccharidosis VI

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioMarin Pharmaceutical

Criteria

Inclusion Criteria:

• Patient consent

• Patient must have successfully completed study ASB-03-05, including having received at least 20 of 24 scheduled weekly infusions and having missed no more then two consecutive infusions

• If female of childbearing potential, patient must have a negative pregnancy test

Exclusion Criteria:

• Pregnant or lactating patient

• Patient has received an investigational drug within 30 days prior to study enrollment

• Patient is unwilling or unable to travel to the primary site for periodic assessments